US20100143497A1 - Compositions and Methods For Promoting Bone Development - Google Patents

Compositions and Methods For Promoting Bone Development Download PDF

Info

Publication number
US20100143497A1
US20100143497A1 US12/528,158 US52815808A US2010143497A1 US 20100143497 A1 US20100143497 A1 US 20100143497A1 US 52815808 A US52815808 A US 52815808A US 2010143497 A1 US2010143497 A1 US 2010143497A1
Authority
US
United States
Prior art keywords
composition
compositions
ppm
feline
fed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/528,158
Other languages
English (en)
Inventor
Ryan Michael Yamka
Kim Gene Friesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hills Pet Nutrition Inc
Original Assignee
Hills Pet Nutrition Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hills Pet Nutrition Inc filed Critical Hills Pet Nutrition Inc
Priority to US12/528,158 priority Critical patent/US20100143497A1/en
Assigned to HILL'S PET NUTRITION, INC. reassignment HILL'S PET NUTRITION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FRIESEN, KIM GENE, YAMKA, RYAN MICHAEL, ZICKER, STEVEN CURTIS
Publication of US20100143497A1 publication Critical patent/US20100143497A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/30—Oligoelements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to compositions and methods for promoting bone development in mammals.
  • pet foods e.g., cat food
  • compositions specially formulated to address many different nutritional needs include, for example, formulations designed for different breed types, sizes and body conditions. They also include formulations designed to address the nutritional needs of animals in the different stages of their life cycle. Despite the availability of such pet food formulations, however, there is a need to develop formulations and methods to address other aspects of an animal's health.
  • Animals are subject to injury, including broken bones and dislocated joints. Animals may also develop degenerative diseases, such as osteoporosis, and osteoarthritis. Accordingly, there is a need for compositions and methods which inhibit such injury and degenerative diseases.
  • Bones are metabolically active, undergoing constant resorption and redeposition of calcium. This requires the sequential and coordinated actions of osteoclasts, to remove bone (resorption), and the osteblasts to replace it (deposition). This is commonly called “bone turnover.” In normal bone, following skeletal growth of an animal, the mineral deposition is in equilibrium with mineral resorption; however, in certain conditions, bone resorption exceeds bone deposition, resulting in loss of bone mineral content. High bone turnover with increased bone resorption can compromise bone strength, leading to a thinning of the bone structure. This may result in abnormal bone microarchitecture and reduced bone mineralization.
  • BAP bone alkaline phosphatase
  • the present invention relates to compositions that are useful to promote bone development in an animal.
  • the present invention includes Composition 1.0, a pet food composition useful to promote bone development in an animal comprising:
  • the present invention also includes the following compositions:
  • compositions of the present invention may be a wet, dry, or semi-dry food.
  • the present invention includes Method 2.0, a method to promote bone development and/or joint health in a feline comprising administering to the feline any one of compositions 1.0-1.18.
  • the present invention also includes the following methods:
  • compositions disclosed herein in addition to administering the compositions disclosed herein directly to a growing animal, e.g., to a growing puppy or kitten, the compositions may be administered to the dam of the animal while the animal is still in utero or while the animal is a nursling.
  • the present invention relates to any animal, preferably a mammal, more preferably a companion animal.
  • the term “companion animal” refers to any animal that lives in close association with humans and includes, but is not limited to, canines and felines of any breed. It is contemplated herein, however, that any animal whose diet may be controlled by humans may benefit from feeding the formulations disclosed herein. These animals may include, for example, domesticated farm animals (e.g., cattle, horses, swine, etc.) as well as undomesticated animals held in captivity, e.g., in zoological parks and the like. Preferably, the animal is a feline, either a kitten, or adult cat.
  • an amount effective to” or “an effective amount” to achieve a particular result refers to that amount of a compound, material or composition as described herein that may be effective to achieve a particularly desired biological result.
  • results include, for example, enhancement of neurologic development, bone and joint health, immune function and/or promotion of a healthy body composition of an animal, either while developing in utero and/or during its growth stage after birth, e.g., up to 6 months, 9 months, 12 months, or 15 months after birth.
  • Such effective activity may be achieved, for example, by administration of compositions of the present invention to the darn of said animal while the animal is in utero or nursing, as well as by direct administration to the animal during its growth stage.
  • the “enhancement” of a particular biological process or body condition in a growing animal refers to an improvement in the biological process or body condition of a growing animal compared to a control animal. Improvement in such a process or condition may be determined by one of skill in the art.
  • “enhancement of the development of a growing animal,” “enhanced growth,” or “promoting growth” and like terms refer to an overall improvement in one or more biological processes and/or the body condition of a growing animal, including but not limited to, biological processes central to the growth and development of an organism, including, but not limited to, the biological processes described herein, e.g., bone and joint health, neurologic and immune system development and body weight gain (e.g., increase in lean muscle mass instead of adipose tissue).
  • the “growth” life stage of an animal refers to the period from birth or weaning (approximately 8 weeks of age) to about 1 year of age.
  • feline refers to an immature feline, typically between the ages of birth and 12 months.
  • “Essential amino acids” as used herein refers to those amino acids that cannot be synthesized de novo by an organism and thus must be supplied in the diet. It is understood by one of skill in the art that the essential amino acids varies from species to species, depending upon the organism's metabolism. For example, it is generally understood that the essential amino acids for dogs and cats (and humans), are phenylalanine, leucine, methionine, lysine, isoleucine, valine, threonine, tryptophan, histidine and arginine. In addition, taurine, while technically not an amino acid but a derivative of cysteine, is considered an essential for cats. A balanced diet can provide all the essential amino acids, however, there are certain essential amino acids that are more critical, as a diet deficient in one of them will limit the usefulness of the others, even if the other essential amino acids are present in sufficient quantities.
  • a “limiting amino acid” refers to an amino acid which if present in insufficient quantities in a diet, results in the limitation in usefulness of other essential amino acids, even if the other essential amino acids are present in otherwise large enough quantities.
  • Lysine is the limiting essential amino acid in the compositions disclosed herein.
  • the remaining essential amino acids are quantitatively formulated or “balanced” in relationship to the amount of lysine determined critical to affect the desired biological result.
  • balanced amino acids refers to the relationship of the essential amino acid lysine to energy to assure optimal animal growth and development.
  • “Essential nutrients” as used herein refers to nutrients required for normal body functioning that cannot be synthesized by the body. Categories of essential nutrient include vitamins, dietary minerals, essential fatty acids, and essential amino acids. It is understood by one of skill in the art that the nutrients deemed essential varies from species to species, depending upon the organism's metabolism. For example, essential nutrients for dogs and cats include Vitamins A, D, E, K, B1, B6, B12, riboflavin, niacin, pantothenic acid, folic acid, calcium, phosphorous, magnesium, sodium, potassium, chlorine, iron, copper, zinc, manganese, selenium and iodine. Choline, generally regarded as a B complex vitamin, may be included among the semi-essential nutrients.
  • Carnitine also known as L-carnitine, (levocarnitine) is a quaternary ammonium compound synthesized from the amino acids lysine and methionine and is responsible for the transport of fatty acids from the cytosol into the mitochondria.
  • the present invention is based on the surprising discovery that the addition of certain ingredients to pet food compositions and administration of these compositions to animals can enhance the bone development/health and/or joint health of a growing animal.
  • Data indicates that animals fed the compositions of the present invention (or those whose dams were fed the compositions during gestation and prior to weaning but continued throughout growth of their litters), demonstrate reduced levels of BAP and deoxypyridinoline.
  • the invention relates to a method to promote the development of bone in an animal comprising administering to said animal a composition of the present invention. Increased bone development may be indicated by reduced levels of BAP or deoxypyridinoline.
  • the invention relates to a method to reduce the BAP and/or deoxypyridinoline levels in an animal comprising administering to the animal a composition of the present invention.
  • Type I collagen tissue is one of the most abundant collagen type in an animal, and is the only collagen type found in mineralized bone, where it accounts for more than 90% of the organic matrix.
  • type I collagen is found in connective tissues, such as joints, together with other collagen types.
  • Carboxyterminal cross-linked telopeptide of type I collagen (“ICTP”) is the carboxyterminal tehopeptide region of type I collagen. The peptide is derived from bone resorption and degradation of connective tissues. It is believed that increased serum concentrations of ICTP is indicative of loss of bone or joint materials.
  • the invention relates to a method to promote the healthy bones and joints in an animal comprising administering to said animal a composition of the present invention.
  • the invention relates to a method to reduce the ICTP, e.g., serum levels, in an animal comprising administering to the animal a composition of the present invention.
  • compositions of the present invention comprise nutritionally complete and balanced animal feed compositions.
  • Such compositions include, among other nutrients and ingredients, recommended healthful amounts of protein, carbohydrate and fat.
  • “Nutritionally complete and balanced animal feed compositions”, as well as nutrients and ingredients suitable for animal feed compositions, and recommended amounts thereof, are familiar to one of skill in the art (see, for example, National Research Council, 2006 Nutritional Requirements for Dogs and Cats, National Academy Press, Washington D.C. or the Official Publication of the Association of American Feed Control Officials, Inc. Nutrient Requirements for Dogs and Cats 2006).
  • compositions disclosed herein may also comprise antioxidants, additives, stabilizers, thickeners, flavorants, palatability enhancers and colorants in amounts and combinations familiar to one of skill in the art.
  • Antioxidants refers to a substance that is capable of reacting with or decreasing the production of free radicals and neutralizing them.
  • Examples include, but are not limited to, beta-carotene, selenium, coenzyme Q10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, vitamin E, vitamin D, vitamin C, flavanoids, anthocyanindins, and lipoic acid.
  • compositions of the present invention may be, for example, a wet, semi-dry or dry animal food composition.
  • “Wet” food refers to food which is sold in cans or foil bags and has a moisture content of about 70% to about 90%.
  • “Dry” food refers to compositions with about 5% to about 15% moisture content and is often manufactured in the form of small bits or kibbles.
  • Semi-dry compositions refer to compositions having about 15% to about 70% moisture.
  • compositions of intermediate moisture consistency and those that may comprise components of various consistency as well as components that may include more than one consistency, for example, soft, chewy meat-like particles as well as kibble having an outer cereal component and an inner cream component.
  • compositions of intermediate moisture consistency and those that may comprise components of various consistency as well as components that may include more than one consistency, for example, soft, chewy meat-like particles as well as kibble having an outer cereal component and an inner cream component as described in, e.g., U.S. Pat. No. 6,517,877.
  • ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may react with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.
  • Formulations to enhance the development of growing animals are disclosed here-in-below. These compositions are developed taking into account the “ideal protein concept” (Baker and Czarnecki-Maulden, 1991 Annu. Rev. Nutr. 11:239-63).
  • Foods are developed for the “growth” life stage. These foods include formulations for canine growth and feline growth. The minimum nutrient recommendations for these foods, as well as the targeted values for a prototype food, are listed below in Table 1.
  • 16 kittens are fed Commercial A1; 16 kittens are fed Commercial B; and 16 kittens are fed Formulation X. Following weaning, the 16 kittens produced from the queens fed Formulation X are maintained on Formulation X.
  • Serum samples are taken from kittens prior to weaning, at 3, 6 and 9 months of age, and are kept frozen until use. Samples are then thawed and subjected to assay as previously described in Yamka, et al., I NTERN J A PPL R ES V ET M ED , Vol 4, No. 3, 2006, and commercial assays as presented in Table 12.
  • Carboxy-terminal c-telopeptide of type I cartilage (ICTP)-Global ANOVA analysis reveals a significant difference between group means at all time points except at 9 months of age.
  • An analysis of the three kitten groups from Formulation A fed dams reveals significant differences between means only at 3 months of age.
  • Deoxy-pyrodiniline (DPD)-Global ANOVA analysis reveals significant differences between means at 3, 6 and 9 months of age. Analysis of the three kitten groups from dams only fed Formulation A yields the same result. Individual t-test comparison between the Formula X-Formula X kittens and the Commercial A-Commercial A1 kittens reveals significant differences at 3 and 6 months of age with the Formula X-Formula X group having a lower value at those two points.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/528,158 2007-02-22 2008-02-22 Compositions and Methods For Promoting Bone Development Abandoned US20100143497A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/528,158 US20100143497A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Promoting Bone Development

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89117107P 2007-02-22 2007-02-22
US12/528,158 US20100143497A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Promoting Bone Development
PCT/US2008/054796 WO2008103956A1 (en) 2007-02-22 2008-02-22 Compositions and methods for promoting bone development

Publications (1)

Publication Number Publication Date
US20100143497A1 true US20100143497A1 (en) 2010-06-10

Family

ID=39563552

Family Applications (6)

Application Number Title Priority Date Filing Date
US12/528,158 Abandoned US20100143497A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Promoting Bone Development
US12/528,164 Active 2030-05-31 US9888709B2 (en) 2007-02-22 2008-02-22 Compositions and methods for enhancing neurological development
US12/528,137 Abandoned US20110059202A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing The Development of Growing Animals
US12/528,153 Abandoned US20100104599A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing Immune System of Felines
US12/528,362 Abandoned US20100137404A1 (en) 2007-02-22 2008-02-22 Compositions and Methods for Altering Gene Expression
US12/876,451 Active US9848622B2 (en) 2007-02-22 2010-09-07 Compositions and methods for enhancing immune system of felines

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/528,164 Active 2030-05-31 US9888709B2 (en) 2007-02-22 2008-02-22 Compositions and methods for enhancing neurological development
US12/528,137 Abandoned US20110059202A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing The Development of Growing Animals
US12/528,153 Abandoned US20100104599A1 (en) 2007-02-22 2008-02-22 Compositions and Methods For Enhancing Immune System of Felines
US12/528,362 Abandoned US20100137404A1 (en) 2007-02-22 2008-02-22 Compositions and Methods for Altering Gene Expression
US12/876,451 Active US9848622B2 (en) 2007-02-22 2010-09-07 Compositions and methods for enhancing immune system of felines

Country Status (12)

Country Link
US (6) US20100143497A1 (enExample)
EP (5) EP2124611B1 (enExample)
JP (5) JP5474570B2 (enExample)
CN (6) CN101686711A (enExample)
AU (5) AU2008218176B2 (enExample)
BR (5) BRPI0807373A2 (enExample)
CA (5) CA2679065C (enExample)
DK (1) DK2129237T3 (enExample)
ES (1) ES2546284T3 (enExample)
RU (5) RU2441394C2 (enExample)
WO (5) WO2008103939A1 (enExample)
ZA (5) ZA200906389B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100104599A1 (en) * 2007-02-22 2010-04-29 Ryan Michael Yamka Compositions and Methods For Enhancing Immune System of Felines
US20140044828A1 (en) * 2011-04-13 2014-02-13 Ajinomoto Co., Inc. Nutritional composition

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937721B1 (en) * 2005-08-25 2010-07-28 Eli Lilly And Company Anti-il-23 antibodies
CN102316865B (zh) * 2008-12-12 2017-04-19 科耐特有限公司 用于改善正常的认知功能的l‑赖氨酸
BR112012015959A2 (pt) 2009-12-29 2019-09-24 Hills Pet Nutrition Inc composições incluindo gengibre para a melhora ou prevenção de condições inflamatórias
EP2568823B1 (en) * 2010-05-12 2016-04-27 Hill's Pet Nutrition, Inc. Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines
RU2551965C2 (ru) * 2010-12-20 2015-06-10 Хилл'С Пет Ньютришн, Инк. Кормовые композиции для домашних животных, вызывающие чувство сытости
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
CN104039823A (zh) 2011-12-19 2014-09-10 希尔氏宠物营养品公司 用于诊断和治疗伴侣动物的甲状腺机能亢进的组合物和方法
CN103315187B (zh) * 2013-07-17 2014-11-05 江苏桂龙生物技术有限公司 一种预防宠物骨骼性疾病的饲料
CN104026401B (zh) * 2014-06-10 2016-04-27 务川县绿之源农业技术推广中心 一种小型幼犬粮
JP6896220B2 (ja) * 2014-10-30 2021-06-30 不二製油株式会社 長鎖多価不飽和脂肪酸含有油脂およびそれを含有する食品
GB201522300D0 (en) * 2015-12-17 2016-02-03 Mars Inc Puppy growth food product
US11617737B2 (en) 2016-12-15 2023-04-04 Société des Produits Nestlé S.A. Compositions and methods that modulate vitamin D and bone mineral content in a companion animal
CN109328020A (zh) 2016-12-15 2019-02-12 雀巢产品技术援助有限公司 用于小型犬科动物的组合物和方法
EP3630088B1 (en) * 2017-05-29 2023-07-12 Société des Produits Nestlé S.A. Medium chain fatty acids for use in the prevention or treatment of valvular heart disease
WO2019155336A1 (en) * 2018-02-08 2019-08-15 Societe Des Produits Nestle S.A. Mct-based nutrition blend for providing health benefits in companion animals
CN108244374A (zh) * 2018-02-27 2018-07-06 佛山市雷米高动物营养保健科技有限公司 猫用营养粉剂及其制备方法
CN113873896B (zh) * 2019-02-01 2025-02-14 马斯公司 猫科动物食品组合物
CN110537630A (zh) * 2019-09-09 2019-12-06 天津农学院 1，2二硫戊环-3-戊酸的应用、幼犬鲜粮和延长幼犬鲜粮贮藏期的方法
JP7626768B2 (ja) * 2019-12-19 2025-02-04 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 成長期の動物に健康上の効果をもたらすための組成物及び方法
US20230165281A1 (en) * 2021-11-29 2023-06-01 Société des Produits Nestlé S.A. Methods and compositions for providing a health benefit in an animal
WO2023150389A1 (en) * 2022-02-07 2023-08-10 Cornell University Compositions and methods for increasing dha availability

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267195A (en) * 1976-09-10 1981-05-12 University Of Texas Dog food flavors
US5690988A (en) * 1996-02-02 1997-11-25 Colgate Palmolive Company Pet food composition of improved palatability and a method of enhancing the palatability of a food composition
US5851573A (en) * 1997-04-29 1998-12-22 The Iams Company Pet food composition for large breed puppies and method for promoting proper skeletal growth
US6071544A (en) * 1999-04-01 2000-06-06 The Iams Company Dietary compositions and method for promoting healthy weight loss cats
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US20020001640A1 (en) * 2000-02-17 2002-01-03 Watkins Bruce A. Method for improving bone modeling and chondrocyte functioning in growing canines
US6517877B2 (en) * 2000-12-29 2003-02-11 Martin Francis Gannon Animal food product
US6582752B2 (en) * 2001-11-02 2003-06-24 Nestec, Ltd Methods and compositions for a gender specific diet for puppies
US20040028719A1 (en) * 2002-07-12 2004-02-12 Davenport Gary Mitchell Synergistic effect of diet and human interaction on the behavior of dogs
US20050014698A1 (en) * 2003-07-07 2005-01-20 Friesen Kim Gene Compositions for improved oxidative status in companion animals
US20050084517A1 (en) * 2003-09-12 2005-04-21 Mars Incorporated Food product for hairball treatment
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US20060045909A1 (en) * 2004-08-30 2006-03-02 Colgate-Palmolive Company Genome-based diet design
US20100093859A1 (en) * 2007-02-22 2010-04-15 Hill's Pet Nutrition, Inc. Compositions and Methods For Enhancing Neurological Development

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130651A (en) * 1978-03-31 1978-12-19 American Cyanamid Company Butamisole injectable formulations having improved margin of safety in dogs
JPH0625057B2 (ja) * 1987-12-14 1994-04-06 日本油脂株式会社 骨形成促進剤
JPH04166039A (ja) * 1990-10-26 1992-06-11 Hirotoshi Yokura ペットフード
GB2367489B (en) * 2000-07-31 2005-02-09 Mars Inc Use of antioxidants
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
AU767764C (en) * 1999-05-27 2005-08-18 Mars, Incorporated Process and product for enhancing immune response in companion animal using a combination of antioxidants
GB2367487A (en) 2000-10-04 2002-04-10 John Kennedy Mcmillan Tooth cleaner
WO2004008196A1 (ja) * 2002-07-13 2004-01-22 Autocloning Technology Ltd. 偏光解析装置
US20050271603A1 (en) 2002-07-26 2005-12-08 Stephanie Krammer Compositions comprising lactoferrin
CA2518197A1 (en) * 2003-03-07 2004-09-23 Advanced Bionutrition Corporation Feed formulation for terrestrial and aquatic animals
WO2004095940A1 (en) 2003-04-25 2004-11-11 The University Of Newcastle Biomass containing animal feed
RU2349312C2 (ru) * 2003-07-03 2009-03-20 Хилл`С Пет Ньютришн, Инк. Композиция и способ для ингибирования ухудшения умственных способностей у кошек
US8921422B2 (en) 2003-10-01 2014-12-30 The Iams Company Methods and kits for enhancing ability to learn in a puppy or kitten
CN1631207A (zh) 2004-12-03 2005-06-29 王志文 能改善猫狗皮毛质量的不饱和脂肪酸饲料添加剂及饲料
ES2579430T3 (es) 2004-12-30 2016-08-11 Hill's Pet Nutrition, Inc. Métodos para aumentar la calidad de vida de un animal en crecimiento
US8148325B2 (en) * 2004-12-30 2012-04-03 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2006299665B2 (en) 2005-09-30 2012-12-13 Nestec S.A. Methods and compositions for improving cognitive function
CA2635655C (en) * 2006-01-10 2011-09-06 Hill's Pet Nutrition, Inc. Compositions and methods for promoting fat loss
CA2660291C (en) * 2006-08-09 2011-11-22 The Iams Company Methods of improving bone health and muscle health

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267195A (en) * 1976-09-10 1981-05-12 University Of Texas Dog food flavors
US4267195B1 (enExample) * 1976-09-10 1989-06-06
US5690988A (en) * 1996-02-02 1997-11-25 Colgate Palmolive Company Pet food composition of improved palatability and a method of enhancing the palatability of a food composition
US5851573A (en) * 1997-04-29 1998-12-22 The Iams Company Pet food composition for large breed puppies and method for promoting proper skeletal growth
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US6071544A (en) * 1999-04-01 2000-06-06 The Iams Company Dietary compositions and method for promoting healthy weight loss cats
US20020001640A1 (en) * 2000-02-17 2002-01-03 Watkins Bruce A. Method for improving bone modeling and chondrocyte functioning in growing canines
US6426100B2 (en) * 2000-02-17 2002-07-30 The Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
US6517877B2 (en) * 2000-12-29 2003-02-11 Martin Francis Gannon Animal food product
US6582752B2 (en) * 2001-11-02 2003-06-24 Nestec, Ltd Methods and compositions for a gender specific diet for puppies
US20040028719A1 (en) * 2002-07-12 2004-02-12 Davenport Gary Mitchell Synergistic effect of diet and human interaction on the behavior of dogs
US20050014698A1 (en) * 2003-07-07 2005-01-20 Friesen Kim Gene Compositions for improved oxidative status in companion animals
US20050084517A1 (en) * 2003-09-12 2005-04-21 Mars Incorporated Food product for hairball treatment
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US20060045909A1 (en) * 2004-08-30 2006-03-02 Colgate-Palmolive Company Genome-based diet design
US20100093859A1 (en) * 2007-02-22 2010-04-15 Hill's Pet Nutrition, Inc. Compositions and Methods For Enhancing Neurological Development

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Nolan Z. Frantz, Ryan M. Yamka, and Kim G. Friesen, "The Effect of Diet and Lysine:Calorie Ratio on Body Composition and Kidney Health in Geriatric Cats", International Journal of Applied Research in Veterinary Medicine, Vol. 5, No. 1, 2007, pp. 25-36. *
Nolan Z. Frantz, Ryan M. Yamka, and Kim G. Friesen, "The Effect of Dietary Protein on Body Composition and Renal Function in Geriatric Dogs", International Journal of Applied Research in Veterinary Medicine, Vol. 5, No. 2, 2007, pp. 57-64. *
Norton W. Milgrama, E. Head, B. Muggenburg, D. Holowachuk, H. Murphey, J. Estrada, C.J. Ikeda-Douglas, S.C. Zicker, and C.W. Cotman, "Landmark discrimination learning in the dog: effects of age, an antioxidant fortified food, and cognitive strategy", Neuroscience and Biobehavioral Reviews, 2002, 26, 679-695. *
Philip Roudebush, "Flatulence: Causes and Management Options", Compendium, December 2001, Vol. 23, No. 12, pp. 1075-1082. *
Ryan M. Yamka, Kim G. Friesen, Steve R. Lowry, and Lori Coffman, "Measurement of Arthritic and Bone Serum Metabolites in Arthritic, Non-Arthritic, and Geriatric Cats Fed Wellness Foods", International Journal of Applied Research in Veterinary Medicine, Vol. 4, No. 3, 2006, pp. 265-273. *
Ryan M. Yamka, Kim G. Friesen, Steve R. Lowry, and Lori Coffman, "Measurement of Arthritic and Bone Serum Metabolites in Arthritic, Non-Arthritic, and Geriatric Dogs Fed Wellness Foods", International Journal of Applied Research in Veterinary Medicine, Vol. 4, No. 3, 2006, pp. 255-264. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100104599A1 (en) * 2007-02-22 2010-04-29 Ryan Michael Yamka Compositions and Methods For Enhancing Immune System of Felines
US20140044828A1 (en) * 2011-04-13 2014-02-13 Ajinomoto Co., Inc. Nutritional composition
US10136669B2 (en) 2011-04-13 2018-11-27 Ajinomoto Co., Inc. Method for decreasing visceral fat or increasing energy consumption

Also Published As

Publication number Publication date
ZA200906387B (en) 2014-03-26
RU2009135260A (ru) 2011-03-27
CA2679682A1 (en) 2008-08-28
RU2435435C2 (ru) 2011-12-10
ZA200906388B (en) 2014-03-26
EP2124610A1 (en) 2009-12-02
JP2010518867A (ja) 2010-06-03
RU2427278C2 (ru) 2011-08-27
EP2124611B1 (en) 2016-01-13
ES2546284T3 (es) 2015-09-22
AU2008218193B2 (en) 2011-09-29
RU2436410C2 (ru) 2011-12-20
US9848622B2 (en) 2017-12-26
AU2008218195C1 (en) 2012-05-24
EP2112889A1 (en) 2009-11-04
AU2008218187B2 (en) 2011-07-07
EP2124611A1 (en) 2009-12-02
CA2679008C (en) 2014-08-12
CN101662950A (zh) 2010-03-03
US20110059138A1 (en) 2011-03-10
US20100104599A1 (en) 2010-04-29
JP5285625B2 (ja) 2013-09-11
JP2010519315A (ja) 2010-06-03
AU2008218195B2 (en) 2011-11-03
CA2678938C (en) 2012-09-18
BRPI0807790B1 (pt) 2017-08-01
JP2010519317A (ja) 2010-06-03
CA2679682C (en) 2012-09-11
AU2008218187C1 (en) 2012-02-16
CN101686711A (zh) 2010-03-31
ZA200906389B (en) 2014-03-26
BRPI0807372A2 (pt) 2014-05-06
AU2008231241B2 (en) 2011-11-10
CN101686712A (zh) 2010-03-31
CN101686712B (zh) 2015-07-22
JP5286287B2 (ja) 2013-09-11
WO2008103956A1 (en) 2008-08-28
CA2679008A1 (en) 2008-08-28
AU2008231241A1 (en) 2008-10-02
EP2129237B1 (en) 2015-06-17
CN101662949A (zh) 2010-03-03
EP2124612B1 (en) 2015-10-21
ZA200908481B (en) 2014-05-28
BRPI0807790A2 (pt) 2014-06-24
BRPI0807691A2 (pt) 2017-05-02
AU2008218176B2 (en) 2011-09-29
US20100137404A1 (en) 2010-06-03
JP5474570B2 (ja) 2014-04-16
WO2008118586A1 (en) 2008-10-02
BRPI0807373A2 (pt) 2014-05-06
AU2008218176A1 (en) 2008-08-28
CA2679065C (en) 2014-07-08
CA2679215C (en) 2015-11-24
CA2679065A1 (en) 2008-10-02
BRPI0807789A2 (pt) 2014-06-24
JP2010518865A (ja) 2010-06-03
JP5474571B2 (ja) 2014-04-16
RU2009135231A (ru) 2011-03-27
US20110059202A1 (en) 2011-03-10
WO2008103958A1 (en) 2008-08-28
JP5286286B2 (ja) 2013-09-11
AU2008218195A1 (en) 2008-08-28
CN101662951A (zh) 2010-03-03
WO2008103939A1 (en) 2008-08-28
RU2412611C1 (ru) 2011-02-27
DK2129237T3 (en) 2015-09-14
RU2009135261A (ru) 2011-03-27
AU2008218187A1 (en) 2008-08-28
RU2009135263A (ru) 2011-03-27
CA2678938A1 (en) 2008-08-28
CN104472871A (zh) 2015-04-01
EP2112889B1 (en) 2015-11-04
RU2441394C2 (ru) 2012-02-10
WO2008103950A1 (en) 2008-08-28
JP2010518866A (ja) 2010-06-03
US20100093859A1 (en) 2010-04-15
CN101662949B (zh) 2013-09-04
EP2124612A1 (en) 2009-12-02
ZA200906390B (en) 2014-08-27
US9888709B2 (en) 2018-02-13
CA2679215A1 (en) 2008-08-28
AU2008218193A1 (en) 2008-08-28
EP2129237A1 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
CA2679008C (en) Compositions and methods for promoting bone development
RU2483569C2 (ru) Композиции для животных-компаньонов, включающие липоевую кислоту, и способы их применения
US11606960B2 (en) Food compositions and methods for preventing copper-associated hepatopathies
CN118303547A (zh) 一种用于宠物尿路结石及泌尿系统调理的湿粮

Legal Events

Date Code Title Description
AS Assignment

Owner name: HILL'S PET NUTRITION, INC.,KANSAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAMKA, RYAN MICHAEL;ZICKER, STEVEN CURTIS;FRIESEN, KIM GENE;SIGNING DATES FROM 20080908 TO 20090921;REEL/FRAME:023727/0858

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION